Anglo–Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca's Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival rate in the company's phase III Mystic lung cancer trial, it was reported yesterday.

The firm has reported the final overall survival results for the phase III Mystic trial, which is a study of Imfinzi monotherapy and the combination of Imfinzi and anti-CTLA4 antibody tremelimumab against standard-of-care platinum-based chemotherapy in earlier-untreated patients with stage IV (metastatic) non-small cell lung cancer.

Imfinzi is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80. Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab have failed to achieve the primary endpoints of improving overall survival compared to standard-of-care chemotherapy in the primary analysis population of patients. Based on the phase III Pacific trial, Imfinzi received approval to treat unresectable and stage III NSCLC in over 40 countries, including the US, EU and Japan.